chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 10:44am, Fainting, drastic drop in blood pressure, blurred vision, numb hands. That evening, chills and vomiting.
Information has been received from a registered nurse concerning a 22-year-old female who on 11-SEP-1085 and 09-JUL-1996 was vaccinated with the first and second doses of MMR II. During a pre-pregnancy screening, the patient had negative titers for measles, mumps, and rubella. No further information on the doses could be obtained. The patient has not had any problems with the negative titers. There was no additional information to report. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
Seizure, diagnosis of epilepsy (complex partial), autism spectrum disorder, developmental delay, chronic constipation (functional).
51 y/o female c/o chest discomfort 15 mins after receiving the first dose of the vaccine. She reported that she has Hx of HTN for which she takes losartan/hctz 50/12.5 mg daily but she did not take it today. She was assessed and monitored by NP, EMT, and paramedic. BP - 161/110, repeated BP - 135/96, HR - 70, resp - 16, 02 sat 98% on RA. She had mild anxiety. She was given H2O and instructed on relaxation techniques. She was kept at site until she reported that she felt better and had no complaints. She instructed to take her BP med as soon as she gets home, monitor her BP, made aware of parameters to report her PCP. She was also given the Vaccination information sheet, reinforced instructions on ADRs/ SEs to call 911 and go to ED, follow up with her PCP and register with V-safe. She verbalized understanding and willingness to comply. She left site in no acute distress, had no complaints, awake, alert, oriented to person, place, time and situation with friend who will be driving her home. She is Spanish speaking, translation was done by RN.
This spontaneous report was received from a medical assistant refers to an unspecified number of patients, age and gender were unknown. Medical history was unknown. In 2014 the patients were vaccinated with M-M-R II (lot number, expiration date, route and dosage were unknown). Which was improperly stored since 20-MAR-2014. No adverse effects reported. Concomitant therapy was unknown. This is one of several reports received from the same reporter. Additional information is not expected because no physician details were provided.
Day of I was dizzy off and on, day after my arm was very sore which I felt was normal. 4/5 I woke up with a very bad headache. 4/6 i woke up with chills, body aches, dizzy
pt recv vax;tested neg for Hep B surface antigen;in sep95,pt was screened & tested pos or hep B surface antigen;
Injection given without unusual pain, but appeared to be at higher site than usual for other vaccinations patient has received.  No immediate reactions.  No redness or swelling at injection site.  Approximately 3 hours later with restriction of abduction of left arm, which became worse over 24 hours.  No numbnness, pain 4-5/10 diffusely over deltoid and in acromium, posterior suprascapular area..  Able to passively move arm, treated with topical Voltaren gel, Naproxyn 500 x 1 dose.  D2 with increased ROM, but still restricted.
Client had a systemic reaction immediately after last shot was given - HPV9. Became dizzy for 20 min. Explained that she had spots in front of her eyes. Became pale but was able to hear instructions. Client stated no respiratory or throat reaction. PHN suggested to family that it is important to see physician as soon as they can today to report what happened and to obtain physician feedback.
Fever day of vaccine, persisted, diabetic severe hyperglycemia, traveled out of state, hospitalized with fever, pulmonary infiltrates, 9/26/15 to 10/1/15.
I woke up the next morning with chills, fever, headache, body aches, and vomiting. It was worse and lasted longer but I did not contact my PCP or treatment. The symptoms did subside in about 4-5 days.
fever 105, rash, probable varicella, varicella lesions to trunk & face;
MENACTRA vaccine administered on 3/19/15. Injection site started to get red on day of injection, increased to size of fist. On day 2, redness increased to size of whole hand. Warm to touch. Due to hx of cellulitis, treated with OMNICEF 600 mg x 10 days.
Rash, itchy on 7/24/16. C/O rash erythematous, non painful, "tad itchy" mom first noticed yesterday, slightly larger today, never hard or painful, more "annoying" was in the sun most of the day and has hx of eczema. Located about 1 inch from injection site on left arm, rash is more over bicep than deltoid. Had MENVEO on Friday.
Case number PHHY2011US60202 is an initial spontaneous report received from a registered nurse on 01 Jul 2011. This report refers to a 19 year old male patient. He was vaccinated with MENVEO (batch number: 090701) intramuscularly on 01 Jul 2011. But he received only Men CYW liquid component without reconstituting it with Men A powder component. No adverse events were reported following this drug administration error.
Per HPI on 1/4: Patient is a 84 y.o. female with history of CVA, pAF on eliquis, GERD, HTN who presents from home today due to weakness, ongoing falls at home and concern for possible CVA. Patient is very hard of hearing and not very participatory in history during my visit with her- daughter at bedside assists. Daughter notes that patient had two episodes of falling earlier in the day and was complaining of mainly weakness in the LE L>R. She does have some residual weakness from prior CVA 3 years ago. Patient lives with her daughter (sister of daughter present) and notes that patient was reluctant to come, but ultimately they called EMS due to persistent falling and concern patient may be having another stroke.    Notably in the ED, patient noted to be hypoxic in the low 90s and covid 19 testing returned +. Daughter and patient note that she is asymptomatic and has not complained of symptoms at home. Daughter (again the sister of daughter present who patient lives with) was covid + 5 days ago and is still in quaruntine. Patient will be admitted to hospitalist service, stroke neurology  Is aware and will see."
tingling in her arms, patient given benadryl and stayed in the post observation area for 30 minutes, symptoms subsided
She got an allergy after the second vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 immunization. The following information was reported: HYPERSENSITIVITY (non-serious), outcome "unknown", described as "She got an allergy after the second vaccine".   Additional information: It was reported that the caller on the line who is reporting side effects for her husband. She is calling on behalf of her husband. Her husband and all her family received the Pfizer COVID 19 BioNtech vaccine. Her husband was the only one with a reaction. The next day after the second dose of the vaccine, he had an allergic reaction. He has a rash and hives especially on his back and shoulder. He is still experiencing this reaction. She called to get it reported, and asked what to do about the side effects. She got an allergy after the second vaccine. She is just worried about this reaction and that there might be an allergy. Her husband did not have a prescribing doctor. There were a lot of hives. The rash and hives showed up the next day after the second dose. His second dose was 12Jul2021, and his first one was 02Jun2021. They have been putting rubbing alcohol on his hives and rash, and they went away. But they keep going away and coming back. It is not constant. They keep coming and going. She was worried because he has had the rash since he had the vaccine. No history of all previous immunization with the Pfizer vaccine considered as suspect. No Additional Vaccines Administered on Same Date of the Pfizer Suspect. No prior Vaccinations (within 4 weeks)  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Migraine level headache with stabbing pain in the back on the head; painful burning, electric shocks, numbness, and weakness in face, arms, hands, legs, and feet. General fatigue.
thought that she was gonna die; Severe allergies 4 days after she got the vaccine, she ended up in the emergency room; This is a spontaneous report received from a contactable reporter(s) from medical information team, Program ID. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: NEAR DEATH EXPERIENCE (medically significant), outcome "unknown", described as "thought that she was gonna die"; HYPERSENSITIVITY(medically significant), 4 days after the suspect product(s) administration, outcome "unknown", described as "Severe allergies 4 days after she got the vaccine, she ended up in the emergency room". The event "thought that she was gonna die" required emergency room visit. The event "severe allergies 4 days after she got the vaccine, she ended up in the emergency room" required physician office visit and emergency room visit. Clinical course: The caller mentioned that she had the second COVID-19 vaccine. She had a severe reaction (severe allergies 4 days after she got the vaccine) and ended up in the emergency room; she thought that she might die. She was referred to an allergist, and she was advised to get the vaccine so that he could do a skin test to find out what it was in the vaccine that she was reacting to.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Considering a plausible drug-event temporal association, a reasonable possibility that the events hypersensitivity and near death experience are related to BNT162b2 (BNT162B2) cannot be excluded. This case will be reassessed should additional information become available.
My heart rate started going up and it continued to go up and it went into the 150's. I went to the doctors and they did an EKG, and prescribed Diastolic. It took several weeks and all test came back normal. I then tested positive for COVID 12/26/2021.
expired vaccine administered; This case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a 22-year-old female patient who received HBV (Engerix B adult) (batch number k2l79, expiry date 12th August 2022) for prophylaxis.   On 3rd October 2022, the patient received Engerix B adult. On 3rd October 2022, unknown after receiving Engerix B adult, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 04-OCT-2022 Reporter's Comment: The pharmacist reported that a dose of Engerix B Adult given to the patient and it was already expired.  The reporter did not consent to follow up.  Additional Supportive Information: The use of Engerix B Adult dose, which was already expired on 12th August 2022, which led to expired vaccine used.
Vaccine Administration Error: The Moderna COVID-19 vaccine is currently authorized under Emergency Use Authorization  (EUA) for individuals 18 years and older. The parents registered their 12 year old son to receive a Moderna vaccine at the drive through clinic. The registration form requires individuals to confirm they are 18 years or older, but no hard stops prevent registration if the age requirement is not met. The mother provided consent for the vaccination at the clinic and Moderna vaccine was given to the child in the adult dose of 100 micrograms, 0.5 ml. After the vaccination was given, the staff member recognized an error had been made and that the child was not eligible for the vaccination given.
Patient experienced a severe back ache and mental confusion (fuzzy thinking) 2 weeks after receiving the vaccine, this episode lasted approximately 3 days. Patient also developed a bilateral "vascular" rash about 2 inches in diameter on each cheek that lasted approximately 1 week and started 2 weeks post vaccination date. Both episodes were self limiting with no treatment.
Swelling and blotchy rash  Onsite of injection on 9/04/2020, approximately 2 hours after vaccine noticed hive  on left jaw line, left cheek under left eye and one on right hand
Patient stated that he has had swelling, redness, and heat at the injection site for 3 days after vaccination.  I instructed patient to alert PCP if area became worse, did not start getting better, and/or if seeing red streaks, or affected area grows.
CDC recommended use of this form to report potential vaccination administration error regarding uncertainty whether vaccine was administered subcutaneously or intramuscularly. Patient was supposed to receive second dose Moderna vaccine via intramuscular injection. Vaccine provider was a nursing student under supervision. Provider stated "This is my first time" and "I didn't feel it go in" multiple times and voiced uncertainty about whether vaccine was administered and called over supervisor for assistance. Supervisor examined syringe and stated "The syringe is empty".  Puncture mark at injection site is present. Patient is concerned whether possible subcutaneous rather than intramuscular delivery of vaccine will reduce vaccine effectiveness. Patient spoke with CDC on 4/30/21 and CDC recommended reporting here.
(Day of) My entire left arm became sore after noon, as well as headache and tiredness. Then as the day continued, I developed a fever and had chills.  (Next day) the entire day my head hurt and my body temperature continued to change. At night I experienced chills and another fever. Fatigue continued since receiving the shot
pt recv vax & exp breakthrough chickenpox;3 patients w/this exp were reported @ this site;
Persistent left arm pain severity right now 2\10 on pain scale, pain max 8/10; lump at injection site day of vaccination, intermittent chills Lump resolved by 2/10/21  Scheduled for dose #2 on 2/18/21
The second dose caused pain in my upper arm/shoulder immediately after the injection and a hard area around the injection site developed throughout the day. The next morning I had noticeable swelling in my lymph nodes in my L armpit and over the next few days it became more swollen and painful and moved to the lymph nodes along my clavicle and into my neck. This lasted for about a week and then took another week to go away completely.
Pt came to the office for injections. Pt recieved dtap/ipv, influenza, and MMR/varicella on 11/18/2019. Pt was given dtap/ipv on rt thigh. Influenza vaccine was given on Lt arm and MMR/varicella was given on Lt thigh.  Pt and mother came for office visit two days later on 11/20/19. Pt mom reports redness, itching and swelling near injection site on both thighs. Redness and swelling was shown more on the Rt thigh. Pt was given symptomatic treatment. Pt was prescribed benadryl and triamcinolone acetonide topical cream.
The Pfizer vaccine that was administered to this patient was in the freezer from 09.14.2021 -10.06.2021, having been expired at that time due to not being transferred from the freezer to the refrigerator prior to 10.06.2021.
Information has been received from a office manager concerning a 72 year old male who on 19-NOV-2007 was vaccinated (route and site not reported) with a 0.5mL dose of pneumococcal 23v polysaccharide vaccine (lot#1229). There was no concomitant medication. On 19-NOV-2007, post vaccination, the patient developed redness on the upper arm, burning, severe pain, hot sensation and was unable to sleep. The patient did receive unspecified medical attention. No diagnostic test were performed. At the time of this report the patient had not recovered. This is one of 2 reports with the same source. Additional information has been requested.
Gradual numbness at injection site (right arm) about 1 ½ hours after injection, numbness spread to shoulder, then down right arm to upper legs.  Tingling in right hand, but full feeling in left hand and both feet. Difficulty standing and walking. Total spread lasting 3 hours, and another 2 ½ to dissipate.
There was a temperature excursion on this vaccine.  It remained in the freezer longer than 2 weeks.  The recommended time frame to be in the freezer.
Office appt 10/31/11 - Mom reports red lump & rash on right thigh at injection site of MMR & Varicella vaccines. Rash spread over entire body & extremities, many scattered petechiae, no purpura, some areas of blanching erythema. Area of about 2cm diameter at injection site with blanching erythema & underlying induration. Also having nose bleeds & bleeding gums.
Afebrile seizure, within 24 hour of vaccines administration.11/28/07-records received for DOS 10/30-10/31/07 DC DX: seczure disorder seconardy to vaccine acministration, most likely rotavirus. Seizure lasted approximately 18 minutes described as staring episode and shaking of upper and lower extremities. No postictal state. No fever. EEG and MRI of brain normal. Rash on right axillary area.
Bumps, rash, chicken-pox like blisters starting from navel and spread to legs and all the way around patient's waist.
I had chills I had severe muscle aches ,throwing up, headache and heart Palpatine  I did feel better on the 25 th but still weak and palpatins
It was reported that a 5 year old male patient received a Tripedia and IPOL vaccination on 11/27/01. The following afternoon the patient developed a large red area at the injection site and a fever 100F. Patient was seen in office; treated of Tylenol was given.
PATIENT PRESENTED FOR 1ST DOSE OF COVID19 VACCINE, DISCLOSED TO US THAT SHE HAD MCAS, BUT WANTED TO GO AHEAD WITH VACCINE WEIGHING RISK/BENEFITS. SO POSSIBILITY OF ANAPHYLAXIS WAS PRESENT AHEAD OF TIME. PATIENT RECEIVED DOSE, THEN SAT DOWN FOR 30 MINUTES, DURING THAT TIME SHE STARTED FEELING FLUSHED, HOT, TONGUE STARTED SWELLING. RPH ON CLINIC PROCEEDED TO GIVE ONE DOSE OF EPI INTRAMUSCULAR THEN WE CONTACTED 911 FOR SQUAD TO COME TAKE CARE OF PATIENT. SQUAD PICKED UP PATIENT AND TRANSPORTED TO HOSPITAL FOLLOWING REACTION.
Premedicated with  Benadryl and then had the following response tingling down left arm, right leg, lips and unusual sensation in abdomen, numbness in right hand and tightening around throat. States that she felt the Benadryl was working and symptoms were less than post 1st dose. today she reports severe arthalgia
atrial fib; This serious case was reported by a physician via sales rep and described the occurrence of atrial fibrillation in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced atrial fibrillation (Verbatim: atrial fib) (serious criteria GSK medically significant). The outcome of the atrial fibrillation was not reported.   It was unknown if the reporter considered the atrial fibrillation to be related to Arexvy.     It was unknown if the company considered the atrial fibrillation to be related to Arexvy.   Additional Information: GSK Receipt Date: 18-OCT-2023 The physician reported that after receiving the dose of Arexvy at the pharmacy patient reported atrial fibrillation. The reporter consented to follow up.
TDAP given in left deltoid on 2/17/08. On 2/25/08, patient calls Employee Health and reports that she has persistent pain in her left shoulder. She states, "It hurts when I adduct it or pick up anything." Patient sent to Medical Clinic for further evaluation. Patient was placed on the following restrictions for 2 weeks: 1) No overhead reaching greater than 2 hours, 2) may not lift or carry more than 20 lbs, 3) attend physical therapy 3 times a week for 2 weeks. She is scheduled for reevaluation at 2 weeks.
Injection given Sub Q intead of IM. Ice pack to arm immediately.  No adverse symptoms. No local irritation or inflammation.
more intense episode of her IBS with diarrhea; more intense episode of her IBS with diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of IRRITABLE BOWEL SYNDROME (more intense episode of her IBS with diarrhea) and DIARRHOEA (more intense episode of her IBS with diarrhea) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030a21a) for COVID-19 vaccination.     The patient's past medical history included No Adverse Event. Concomitant products included THYROID (ARMOUR THYROID), prozac/fluoxetine, TRAZODONE, ZINC, MAGNESIUM, CALCIUM, CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000), ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP) and CALCIUM CARBONATE, MAGNESIUM CARBONATE, MAGNESIUM TRISILICATE, SODIUM BICARBONATE (PEPPERMINT INDIGESTION) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IRRITABLE BOWEL SYNDROME (more intense episode of her IBS with diarrhea) and DIARRHOEA (more intense episode of her IBS with diarrhea). At the time of the report, IRRITABLE BOWEL SYNDROME (more intense episode of her IBS with diarrhea) and DIARRHOEA (more intense episode of her IBS with diarrhea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-089287 (Patient Link).
Patient received Pfizer booster shot as 3rd dose, upon later investigation the patient had received Moderna as the first 2 shots. No adverse effects reported at this time. Will follow up with patient in the next couple days.
Patient developed urticaria after shots. Will treat with ZYRTEC daily for 7 days.
No additional AE reported; Patient was administered expired MMRII; This spontaneous report was received from a nurse and refers to an 1-year-old patient. The patient's pertinent medical history, concurrent conditions, previous drug allergies or reactions, and concomitant medications were not provided.  On 28-APR-2022, the patient was vaccinated with a expired measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant human albumin rHA) (M-M-R II) lot T013724, expiration date reported as 21-APR-2022 (strength, and route of administration were not provided) (expired product administered). No additional adverse event was reported.
Side effects; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects). At the time of the report, VACCINATION COMPLICATION (Side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant products usage were not reported by the reporter.  Treatment details not included.
3/9/04 Hep B #3 administered- outdated. 5/4/04 Hep B #3 re-administered.
Pt who is reporting MD rec'd immunization following an injury. 1 day later, there was swelling at the inject site & he felt feverish. sx lasted 2 days.
DTaP administered 11/22/2005. 11/23/2005 Thigh swollen, tender, red. Ice and Benadryl. 11/24/2005 increased swelling and pain sent to ER
Bruise on deltoid where vaccine given about 1 3/4 inches in diameter.